查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827950

血友病治療市場按治療層級、治療模式、最終用戶和分銷管道分類－2025-2032 年全球預測

Hemophilia Treatment Market by Therapeutic Class, Treatment Mode, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血友病治療市場規模將成長至 254.8 億美元，複合年成長率為 6.64%。

主要市場統計數據
基準年2024年 152.3億美元
預計2025年 162.6億美元
預測年份：2032年 254.8億美元
複合年成長率（%） 6.64%

對當前血友病治療動態、臨床進展、患者期望以及相關人員決策的策略重點有清晰且令人信服的定位

在科學突破、治療方式轉變以及支付者和政策制定者日益成長的關注的推動下，血友病治療領域正在迅速演變。近期的治療方法創新正在重塑圍繞持續獲益和改善生活品質的臨床討論，促使相關人員重新評估臨床路徑和長期照護模式。同時，患者的期望也在改變。患者和看護者都越來越尋求能夠降低出血頻率、簡化給藥並最大程度減少生活方式干擾的治療方法。這些期望正在影響臨床醫生、衛生系統和製造商的投資和服務設計重點。

同時，監管機構正在調整新治療方法的核准路徑，並制定循證策略和核准後監測計畫。支付方也同樣加強了對比較有效性和總醫療成本的審查，鼓勵製造商將其上市策略與價值證明和基於結果的合約相結合。同時，診斷技術和數位醫療解決方案的進步也增強了監測能力，並帶來了更主動的管理。總而言之，這些動態為尋求實現永續患者為中心的醫療保健的開發商、醫療保健提供者和政策制定者帶來了機遇，也帶來了複雜性。

科學突破、付款人演變和分散護理模式的融合如何重塑整個血友病生態系統的臨床應用和策略重點

在科學創新、支付者行為和醫療服務現代化的共同作用下，血友病領域正在發生一場變革性轉變。基因編輯和基因替代療法正在推動人們從長期替代療法轉向更持久解決方案的潛在轉變，從而重塑臨床試驗設計、長期追蹤計畫和生產策略。同時，替代療法的改進，包括延長半衰期的製劑和替代給藥方式，正在持續減輕治療負擔並擴大治療選擇。

付款人參與度正從交易報銷逐漸成熟，轉向關注治療結果和總成本，這獎勵製造商展示其在現實世界中的有效性和患者報告的治療結果。同時，醫療服務交付也日益分散，家庭輸液、遠端監控和社區專科診所如今能夠適應複雜的治療方案。從數位化依從性工具到遠端因素層級監控，科技推動因素正在減少個人化醫療的障礙，同時產生新的證據類型。這些力量正在匯聚，創造一種新格局：策略敏捷性、強大的證據產生能力和以患者為中心的服務將決定哪些創新技術能夠獲得廣泛的臨床應用並保持商業性可行性。

不斷變化的關稅政策對採購、物流和合約結構的實際影響會影響血友病治療的連續性和商業性穩定性。

2025年，關稅框架和跨境貿易政策的調整，為籌資策略、供應鏈韌性以及各治療類別的價格談判帶來了重要的考量。製造商和經銷商正在重新評估其採購足跡和物流，以減少可能影響醫療保健系統和患者負擔能力的潛在成本轉嫁。為此，許多相關人員優先考慮供應鏈的可視性和合約的靈活性，以應對間歇性的成本波動和海關相關的延誤。

採購團隊越來越青睞多元化的供應商網路和近岸外包方案，以降低關稅波動帶來的風險。同時，合約策略正轉向長期協議，其中包含明確的服務水準和緊急條款，以維持醫療服務的連續性。這些變化也促使製造商重新考慮地域發布順序，並改善與付款人和醫療系統的價值溝通，因為這些系統在關稅引發的成本壓力方面最為顯著。最終，關稅變化的累積影響凸顯了整合商業和營運規劃的必要性，以便在保障患者用藥管道的同時保持商業性永續性。

全面洞察治療方式、治療形式、治療環境和通路的細分，揭示差異化的價值創造機會

以細分為重點的洞察揭示了臨床需求、治療環境和通路的交匯點，從而影響採用路徑和服務設計。從治療層級維度來看，基因療法與替代療法展現出不同的發展重點。基因為基礎的療法需要長期的安全監測、專業化生產和已證實的療效，而替代療法則注重給藥的便捷性、供應鏈的可靠性和臨床差異化。另一方面，按需療法則強調快速取得、急性護理協調和緊急應變。

考慮最終使用者概況（家庭醫療保健、醫院、專科診所）可以揭示護理環境如何影響服務要求和商業性推廣。家庭醫療保健模式需要分散分銷、看護者教育和遠端監控解決方案，而以醫院為中心的照護則強調機構處方、住院物流和急性護理整合。專科診所是複雜個案管理、多學科協作和註冊主導證據收集的中心。最後，分析醫院和零售藥局的通路可以揭示採購路徑和病患接觸點的差異。醫院藥局通常負責機構承包和住院支持，而零售藥局則影響門診病人依從性、可及性和社區級病患教育。整合治療層級、治療模式、最終使用者和分銷管道的觀點，使相關人員能夠確定與針對每個患者群體的價值提案一致的服務模式。

全球主要地區在監管、報銷和醫療保健服務方面的差異如何導致差異化的獲取動態和商業性方法

區域動態塑造監管預期、醫療服務提供規範和支付方框架，並直接影響臨床應用和商業策略。在美洲，創新的採用通常伴隨著支付方的嚴格審查和複雜的基於結果的合約試點。公共和私人支付方需要全面的證據和真實世界數據來證明高成本干預措施的合理性，而病患權益團體則影響可及性途徑和政策重點。各州和領地之間的政策差異使得區域參與策略成為必要，這又增加了一層複雜性。

在歐洲、中東和非洲，多樣化的監管結構和報銷途徑需要量身定做的市場策略。有些國家強調集中式衛生技術評估和價值論證，而有些國家則維持分散式採購機制，優先考慮成本控制和處方集管理。在資源匱乏的環境中，藥物的可及性通常依賴分級定價模式以及與非政府組織的夥伴關係。在亞太地區，快速現代化的醫療保健體系和龐大的公共支付方既帶來了機遇，也帶來了限制。雖然某些地區的監管靈活性可能會加快新療法的核准，但報銷時間表和預算影響評估仍然是藥物採用的關鍵決定因素。綜上所述，這些區域特徵凸顯了將臨床證據產生、定價策略和相關人員參與與當地監管機構和支付方期望相協調的重要性。

成功企業在不斷發展的血友病護理領域所特有的關鍵能力、夥伴關係模式和證據策略

公司層面的動態決定了哪些公司已取得臨床進展並永續獲得藥物，哪些公司面臨重重障礙。策略領導力、生產規模和強大的證據產生能力，使先進療法的先驅和成熟的生技藥品製造商能夠應對複雜的監管環境，並確保報銷談判順利進行。投資於分散式生產能力、低溫運輸物流和治療中心專業培訓計畫的公司，可以顯著減少啟動摩擦，並支持持續治療。

研發公司、專業藥局、付款方和供應商網路之間的合作，促進了病患識別、治療啟動和縱向監測的整合路徑。數位化依從性平台、遠端醫療追蹤和集中式註冊等技術整合，透過產生真實世界的結果和提高患者保留率，擴展了價值提案。相反，在上市後證據和相關人員參與方面投入不足的公司，往往會面臨付款方的抵制，臨床應用進展緩慢。總而言之，最成功的公司展現出將科學差異化與卓越營運、牢固的相關人員以及以臨床、經濟和患者為中心的證據策略相結合的能力。

領導團隊可採取的策略重點，以協調證據產生、供應彈性、付款人參與和以病人為中心的服務，從而產生持久影響

行業領導者應採取一系列優先行動，使臨床創新與付款人期望、營運彈性和以患者為中心的設計保持一致。首先，將可靠的真實世界證據納入開發計劃，以預測付款人需求並支持基於結果的合約。將註冊、遠端監控和患者報告的結果納入核准後計劃，使公司能夠展示持續的臨床效益並闡明其價值提案。其次，投資於供應鏈靈活性和區域物流，以減輕與關稅相關的中斷，並確保患者能夠不間斷地獲得藥物。近岸外包、供應商多元化以及與經銷商簽訂應急協議有助於保持連續性。

第三，制定個人化的上市方案，以反映當地監管和報銷的細微差別。儘早與衛生技術評估機構合作，調整經濟模型以反映實際治療路徑，並準備有針對性的臨床和付款方材料。第四，加強病患支持基礎設施，以促進居家照護、遵從性和心理社會支持。最後，促進付款方與醫療服務提供者之間的夥伴關係，探索創新的合約方式、風險分擔安排和綜合護理路徑。這些綜合行動可以加速先進治療方法的負責任應用，同時保障病患的可及性並展現永續的價值。

透明的混合方法研究設計將專家的初步訪談與系統的二次分析相結合，提供了基於相關人員的可複製的見解

為了確保觀點平衡、結論可靠，我們將結構化的一手資料研究與系統性的二次研究結合。一手資料包括與臨床專家、付款人、供應鏈專業人員和患者權益代表的深入訪談，以了解實踐現狀、報銷考慮和生活體驗。這些對話推動了假設驅動型研究的發展，並指南了有針對性的後續研究，以檢驗新興主題。二次性研究綜述涵蓋同儕審查文獻、監管指南、臨床試驗報告和公共文件，以支持在當前科學和監管背景下的解讀。

數據三角測量用於協調不同的輸入，並突出相關人員之間的共同見解。該方法包括定性編碼以識別重複出現的主題，以及基於情境的分析以探索針對政策和市場變化的合理營運回應。在適當的情況下，確定了調查方法的局限性和邊界條件，包括需要持續累積證據的領域，例如新治療方法的長期安全性和現實世界有效性。資料來源、受訪者概況和分析假設的透明度支持可複製性，並允許使用者將研究結果應用於自己的策略框架。

簡潔的綜合強調了相關人員的協作、證據的完整性和操作的敏捷性是將創新轉化為病患可及性的關鍵因素。

血友病治療領域正處於曲折點，科學進步、支付方審查和商業需求交織在一起。持久的治療創新有望減輕治療負擔並改善患者預後，但實現這一目標需要有針對性的實證策略、韌性十足的供應鏈以及細緻入微的市場參與。相關人員若能積極主動地將臨床開發與支付方需求結合，投資於病患支援和監測基礎設施，並根據當地情況自訂分銷策略，則最有可能將創新轉化為可及的醫療保健。

持續的進步需要製造商、醫療保健提供者、付款人和患者群體通力合作，共同創造平衡臨床效益與可負擔性和公平可及性的途徑。持續監測監管和政策變化、投資真實世界證據以及提高營運靈活性至關重要。面對複雜的情況，清晰的策略和跨部門合作將決定哪些治療方法能為血友病患者帶來有意義且可擴展的影響。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 基於 CRISPR 的基因治療方法在A型血友病 A中的廣泛應用提供了持續的因子表達，減少了終生輸血的需要
  • 艾美珠單抗等雙特異性單株抗體治療的擴展正在重塑存在抑制劑開發風險的A型血友病 A患者的預防通訊協定
  • 穿戴式科技與數位依從性平台的整合度不斷提高，可即時監測出血事件和液體依從性
  • 與一次性基因療法（如批量 cocogenic loxaparvovec）相關的監管和定價挑戰正在影響市場進入和報銷決策。
  • 利用國際血友病登記處的真實世界數據來制定個人化預防方案和綜合健康經濟模型
  • 開發半衰期延長的重組因子 VIII 和因子 IX 產品，延長給藥間隔，以提高患者的便利性和生活品質
  • 新興的以患者為中心的結果測量和遠端醫療服務，以最佳化血友病患者群體的遠距照護管理和依從性支持

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：血友病治療市場（依治療層級）

  • 基因治療
  • 替代療法

9. 血友病治療市場（依治療模式）

  • 一經請求
  • 預防

第 10 章 血友病治療市場（依最終用戶分類）

  • 家庭醫療保健
  • 醫院
  • 專科診所

第 11 章血友病治療市場（依通路）

  • 醫院藥房
  • 零售藥局

第12章血友病治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章血友病治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 血友病治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Roche Holding AG
    • Takeda Pharmaceutical Company Limited
    • Swedish Orphan Biovitrium AB
    • Bayer AG
    • CSL Limited
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Octapharma AG
    • Grifols, SA
    • BioMarin Pharmaceutical Inc.
Product Code: MRR-4316E4E894CE

The Hemophilia Treatment Market is projected to grow by USD 25.48 billion at a CAGR of 6.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.23 billion
Estimated Year [2025] USD 16.26 billion
Forecast Year [2032] USD 25.48 billion
CAGR (%) 6.64%

A clear and compelling orientation to current hemophilia care dynamics, clinical advances, patient expectations, and the strategic priorities shaping stakeholder decisions

The hemophilia treatment landscape is undergoing a rapid period of evolution driven by scientific breakthroughs, shifts in care delivery, and heightened attention from payers and policymakers. Recent therapeutic innovations have reframed clinical conversations around durable benefit and quality-of-life improvements, prompting stakeholders to reassess clinical pathways and long-term care models. At the same time, patient expectations are changing: individuals and caregivers increasingly seek treatments that reduce bleeding frequency, simplify administration, and minimize lifestyle disruption. These expectations are influencing how clinicians, health systems, and manufacturers prioritize investment and service design.

Concurrently, regulatory authorities have adjusted pathways to account for novel modalities, shaping evidence-generation strategies and post-approval monitoring plans. Payers have likewise intensified scrutiny on comparative effectiveness and total cost of care, which encourages manufacturers to align launch strategies with value demonstration and outcomes-based contracting. In parallel, advances in diagnostics and digital health solutions are enhancing monitoring capabilities and enabling more proactive management. Taken together, these dynamics create both opportunity and complexity for developers, providers, and policy-makers seeking to deliver sustainable, patient-centric care.

How converging scientific breakthroughs, payer evolution, and decentralized care models are reshaping clinical adoption and strategic priorities across the hemophilia ecosystem

Transformative shifts in the hemophilia space are emerging from confluence of scientific innovation, payer behavior, and care delivery modernization. Gene-editing and gene-replacement approaches are prompting long-range thinking about a potential shift from chronic replacement regimens to more durable solutions, which in turn is reshaping clinical trial design, long-term follow-up plans, and manufacturing strategies. At the same time, improvements in replacement therapies, including extended half-life products and alternative delivery formats, continue to lower treatment burden and expand therapeutic choice.

Payer engagement has matured from transactional reimbursement to an emphasis on outcomes and total cost of care, creating incentives for manufacturers to prove real-world effectiveness and patient-reported outcomes. Meanwhile, care delivery is decentralizing as home-based infusion, remote monitoring, and specialized community clinics become more capable of supporting complex regimens. Technological enablers-from digital adherence tools to remote factor-level monitoring-are reducing barriers to individualized care while generating new types of evidence. Together, these forces are creating a landscape in which strategic agility, robust evidence generation, and patient-centered services determine which innovations achieve widespread clinical adoption and sustained commercial viability.

Practical implications of evolving tariff policies on procurement, logistics, and contractual structures that affect access continuity and commercial stability in hemophilia treatments

In 2025, adjustments to tariff frameworks and cross-border trade policies have created material considerations for procurement strategies, supply chain resilience, and pricing negotiations across therapeutic categories. Manufactures and distributors are reassessing sourcing footprints and logistics to mitigate potential cost pass-throughs that can affect affordability for both health systems and patients. In response, many stakeholders are prioritizing supply chain visibility and contractual flexibility to manage intermittent cost fluctuations and customs-related delays.

Procurement teams are increasingly favoring diversified supplier networks and nearshoring options to reduce exposure to tariff volatility. Concurrently, contracting strategies are shifting toward longer-term agreements with defined service levels and contingency clauses to preserve continuity of care. These changes are also prompting manufacturers to reconsider geographic launch sequencing and to refine value communication to payers and health systems where tariff-induced cost pressures are most pronounced. Ultimately, the cumulative impact of tariff changes emphasizes the need for integrated commercial and operational planning to protect patient access while maintaining commercial sustainability.

Comprehensive segmentation insights connecting therapeutic modalities, treatment modes, care settings, and distribution pathways to reveal differentiated value creation opportunities

Segment-focused insights reveal where clinical needs, care settings, and delivery channels intersect to influence adoption pathways and service design. When studying the therapeutic class dimension, the contrast between gene therapy and replacement therapy clarifies divergent development priorities: gene-based approaches require long-term safety surveillance, specialized manufacturing, and outcomes demonstration, whereas replacement therapies concentrate on dosing convenience, supply chain reliability, and incremental clinical differentiation. From the treatment mode perspective, the distinction between on-demand treatments and prophylaxis illuminates differing patient engagement models and resource utilization; prophylactic regimens center on preventing bleeding episodes and supporting continuous adherence programs, while on-demand approaches emphasize rapid access, acute care coordination, and emergency readiness.

Consideration of end user profiles-home healthcare, hospitals, and specialized clinics-shows how care setting influences service requirements and commercial outreach. Home healthcare models demand decentralized distribution, caregiver education, and remote monitoring solutions, whereas hospital-centric care leans on institutional formularies, inpatient logistics, and acute care integration. Specialized clinics act as hubs for complex case management, multidisciplinary coordination, and registry-driven evidence collection. Finally, distribution channel analysis across hospital pharmacy and retail pharmacy underscores different procurement pathways and patient touchpoints; hospital pharmacies often handle institutional contracting and inpatient support, while retail pharmacies influence outpatient adherence, accessibility, and community-level patient education. By integrating therapeutic class, treatment mode, end user, and distribution channel perspectives, stakeholders can identify tailored value propositions and aligned service models for distinct patient cohorts.

How regional regulatory, reimbursement, and care delivery variations across major global regions translate into differentiated access dynamics and commercial approaches

Regional dynamics shape regulatory expectations, care delivery norms, and payer frameworks in ways that directly affect clinical adoption and commercial strategy. In the Americas, innovation adoption is often accompanied by intense payer scrutiny and sophisticated outcomes-based contracting pilots; public and private payers demand comprehensive evidence packages and real-world data to justify higher-cost interventions, while patient advocacy groups influence access pathways and policy priorities. Policy variation across states and provinces adds another layer of complexity that requires localized engagement strategies.

Across Europe, Middle East & Africa, diverse regulatory architectures and reimbursement pathways necessitate bespoke market approaches. Some countries emphasize centralized health technology assessment and value demonstration, while others maintain decentralized procurement mechanisms that prioritize cost containment and formulary management. Access in lower-resource settings often hinges on tiered pricing models and partnerships with non-governmental organizations. In the Asia-Pacific region, a mix of rapidly modernizing healthcare systems and large public payers creates both opportunity and constraint. Regulatory agility in certain jurisdictions can accelerate approvals for novel therapies, but reimbursement timelines and budget impact assessments remain critical determinants of uptake. Collectively, these regional characteristics underline the importance of aligning clinical evidence generation, pricing strategy, and stakeholder engagement with local regulatory and payer expectations.

Critical organizational capabilities, partnership models, and evidence strategies that distinguish successful companies in the evolving hemophilia treatment landscape

Company-level dynamics distinguish organizations that achieve clinical traction and sustainable access from those that face roadblocks. Strategic leadership, manufacturing scale, and robust evidence-generation capabilities enable advanced therapy pioneers and established biologics manufacturers to navigate complex regulatory landscapes and secure reimbursement dialogues. Firms that invest in distributed manufacturing capacity, cold-chain logistics, and specialized training programs for treating centers can materially reduce launch friction and support continuity of care.

Partnership models are also critical: collaborations between developers, specialty pharmacies, payers, and provider networks facilitate integrated pathways for patient identification, initiation of therapy, and long-term monitoring. Technology integration-such as digital adherence platforms, telehealth-enabled follow-up, and centralized registries-amplifies the value proposition by producing real-world outcomes and improving patient retention. Conversely, companies that under-invest in post-market evidence and stakeholder engagement often encounter payer pushback and slower clinical adoption. In sum, the most successful organizations demonstrate an ability to combine scientific differentiation with operational excellence, strong stakeholder relationships, and an evidence strategy that speaks to clinical, economic, and patient-centered endpoints.

Actionable strategic priorities for leadership teams to align evidence generation, supply resilience, payer engagement, and patient-centered services for sustained impact

Industry leaders should pursue a set of prioritized actions that align clinical innovation with payer expectations, operational resilience, and patient-centered design. First, embed robust real-world evidence generation into development plans to anticipate payer needs and support outcomes-based contracting. By integrating registries, remote monitoring, and patient-reported outcomes into post-approval programs, organizations can demonstrate sustained clinical benefits and inform value propositions. Second, invest in supply chain flexibility and regional logistics to mitigate tariff-related disruptions and ensure uninterrupted patient access; nearshoring, diversified suppliers, and contingency agreements with distributors can preserve continuity.

Third, develop bespoke launch playbooks that reflect local regulatory and reimbursement nuances: engage early with health technology assessment bodies, tailor economic models to reflect real-world care pathways, and prepare targeted materials for clinical and payer audiences. Fourth, strengthen patient support infrastructures that facilitate home-based care, adherence, and psychosocial support; comprehensive patient services increase persistence and optimize clinical outcomes. Finally, cultivate payer and provider partnerships that explore innovative contracting approaches, risk-sharing arrangements, and integrated care pathways. These combined actions will accelerate responsible adoption of advanced therapies while protecting patient access and demonstrating sustainable value.

A transparent, mixed-methods research design combining expert primary interviews and systematic secondary analysis to deliver reproducible, stakeholder-informed insights

The research approach combined structured primary engagement with systematic secondary synthesis to ensure balanced perspectives and credible conclusions. Primary inputs included in-depth interviews with clinical experts, payers, supply chain professionals, and patient advocacy representatives to capture operational realities, reimbursement considerations, and lived experience. These conversations informed the development of hypothesis-driven inquiry and guided targeted follow-up to validate emerging themes. Secondary review encompassed peer-reviewed literature, regulatory guidance, clinical trial reports, and public policy documents to anchor interpretations in current scientific and regulatory contexts.

Data triangulation was used to reconcile disparate inputs and to highlight convergent insights across stakeholders. The methodology included qualitative coding to identify recurrent themes and scenario-based analysis to explore plausible operational responses to policy and market shifts. Where appropriate, methodological limitations and boundary conditions were identified, including areas requiring ongoing evidence accumulation such as long-term safety and real-world effectiveness for novel modalities. Transparency about data sources, interview respondent profiles, and analytic assumptions supports reproducibility and helps users apply the findings within their own strategic frameworks.

A concise synthesis emphasizing cross-stakeholder collaboration, evidence alignment, and operational agility as the decisive factors for translating innovation into patient access

The hemophilia treatment environment is at an inflection point where scientific progress, payer scrutiny, and operational imperatives converge. Durable therapeutic innovations create the promise of reduced treatment burden and improved patient outcomes, yet realizing that promise depends on intentional evidence strategies, resilient supply chains, and finely tuned market engagement. Stakeholders that proactively align clinical development with payer requirements, invest in patient support and monitoring infrastructures, and adapt distribution strategies to regional realities will be best positioned to convert innovation into accessible care.

Sustained progress will require collaboration across manufacturers, providers, payers, and patient communities to co-create pathways that balance clinical benefit with affordability and equitable access. Continued monitoring of regulatory and policy shifts, investment in real-world evidence, and agility in operational execution are essential. In the face of complexity, strategic clarity and cross-functional coordination will determine which therapies achieve meaningful, scalable impact for people living with hemophilia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of CRISPR-based gene therapy approaches in hemophilia A to achieve durable factor expression and reduce lifelong infusion requirements
  • 5.2. Expansion of bispecific monoclonal antibody treatments such as emicizumab reshaping prophylaxis protocols for hemophilia A patients with inhibitor development risk
  • 5.3. Growing integration of digital treatment adherence platforms and wearable technology to monitor bleeding episodes and infusion compliance in real time
  • 5.4. Regulatory and pricing challenges associated with one-time gene therapies like valoctocogene roxaparvovec influencing market access and reimbursement decisions
  • 5.5. Utilization of real-world data from international hemophilia registries to inform personalized prophylactic regimens and comprehensive health economic modeling
  • 5.6. Development of extended half-life recombinant factor VIII and IX products extending dosing intervals to improve patient convenience and quality of life
  • 5.7. Emergence of patient-centric outcome measures and telemedicine services optimizing remote care management and adherence support for hemophilia populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hemophilia Treatment Market, by Therapeutic Class

  • 8.1. Gene Therapy
  • 8.2. Replacement Therapy

9. Hemophilia Treatment Market, by Treatment Mode

  • 9.1. On-Demand
  • 9.2. Prophylaxis

10. Hemophilia Treatment Market, by End User

  • 10.1. Home Healthcare
  • 10.2. Hospitals
  • 10.3. Specialized Clinics

11. Hemophilia Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Retail Pharmacy

12. Hemophilia Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hemophilia Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hemophilia Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Holding AG
    • 15.3.2. Takeda Pharmaceutical Company Limited
    • 15.3.3. Swedish Orphan Biovitrium AB
    • 15.3.4. Bayer AG
    • 15.3.5. CSL Limited
    • 15.3.6. Novo Nordisk A/S
    • 15.3.7. Pfizer Inc.
    • 15.3.8. Octapharma AG
    • 15.3.9. Grifols, S.A.
    • 15.3.10. BioMarin Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 71. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 129. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 133. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 134. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 156. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 166. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 167. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 186. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 196. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 197. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 206. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 207. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 225. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 233. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 241. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 257. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 265. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 273. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 281. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 289. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 296. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 297. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 304. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 305. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 310. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 311. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 312. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 313. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 320. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 326. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 328. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 334. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024